Matthew S Davids, MD | |
450 Brookline Ave, Boston, MA 02215-5418 | |
(617) 632-3000 | |
(617) 632-5822 |
Full Name | Matthew S Davids |
---|---|
Gender | Male |
Speciality | Medical Oncology |
Experience | 19 Years |
Location | 450 Brookline Ave, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659541522 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | 234844 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Brigham And Women's Hospital | Boston, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
Researchers in Japan have developed a new photodiode that can detect in just milliseconds a certain type of high-energy ultraviolet light, called UVC, which is powerful enough to break the bonds of DNA and harm living creatures. The researchers describe their new device in the journal Applied Physics Letters.
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Four tiny segments of RNA appear to play critical roles in controlling cholesterol and triglyceride metabolism. In their report receiving advance online publication in Nature Medicine, a Massachusetts General Hospital-based research team describes finding how these microRNAs could reduce the expression of proteins playing key roles in the generation of beneficial HDL cholesterol, the disposal of artery-clogging LDL cholesterol, control of triglyceride levels and other risk factors of cardiovascular disease.
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.
› Verified 9 days ago
Entity Name | Dana-farber Cancer Institute, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1346433257 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000142 |
News Archive
Researchers in Japan have developed a new photodiode that can detect in just milliseconds a certain type of high-energy ultraviolet light, called UVC, which is powerful enough to break the bonds of DNA and harm living creatures. The researchers describe their new device in the journal Applied Physics Letters.
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Four tiny segments of RNA appear to play critical roles in controlling cholesterol and triglyceride metabolism. In their report receiving advance online publication in Nature Medicine, a Massachusetts General Hospital-based research team describes finding how these microRNAs could reduce the expression of proteins playing key roles in the generation of beneficial HDL cholesterol, the disposal of artery-clogging LDL cholesterol, control of triglyceride levels and other risk factors of cardiovascular disease.
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.
› Verified 9 days ago
Entity Name | Dana-farber Cancer Institute, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
Researchers in Japan have developed a new photodiode that can detect in just milliseconds a certain type of high-energy ultraviolet light, called UVC, which is powerful enough to break the bonds of DNA and harm living creatures. The researchers describe their new device in the journal Applied Physics Letters.
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Four tiny segments of RNA appear to play critical roles in controlling cholesterol and triglyceride metabolism. In their report receiving advance online publication in Nature Medicine, a Massachusetts General Hospital-based research team describes finding how these microRNAs could reduce the expression of proteins playing key roles in the generation of beneficial HDL cholesterol, the disposal of artery-clogging LDL cholesterol, control of triglyceride levels and other risk factors of cardiovascular disease.
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Matthew S Davids, MD 450 Brookline Ave, Boston, MA 02215-5418 Ph: (617) 632-3000 | Matthew S Davids, MD 450 Brookline Ave, Boston, MA 02215-5418 Ph: (617) 632-3000 |
News Archive
Researchers in Japan have developed a new photodiode that can detect in just milliseconds a certain type of high-energy ultraviolet light, called UVC, which is powerful enough to break the bonds of DNA and harm living creatures. The researchers describe their new device in the journal Applied Physics Letters.
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Four tiny segments of RNA appear to play critical roles in controlling cholesterol and triglyceride metabolism. In their report receiving advance online publication in Nature Medicine, a Massachusetts General Hospital-based research team describes finding how these microRNAs could reduce the expression of proteins playing key roles in the generation of beneficial HDL cholesterol, the disposal of artery-clogging LDL cholesterol, control of triglyceride levels and other risk factors of cardiovascular disease.
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.
› Verified 9 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |